Compass files psilocybin application for resistant depression; FDA reportedly shelves priority voucher program; lumateperone meets mania end point

Listen to this post
read by AI voices · all episodesCompass Pathways said it completed its new drug application to the Food and Drug Administration (FDA) for COMP360 psilocybin in treatment-resistant depression, a product that holds a National Priority Voucher. The FDA has reportedly shelved that voucher program, Johnson & Johnson reported a second positive phase 3 trial of lumateperone in bipolar mania, and the American Society of Addiction Medicine (ASAM) issued medetomidine guidance.
- FDA Nov 9, 2026Compass Pathways said on Nov. 9 that it completed its submission of a new drug application to the Food and Drug Administration (FDA) for COMP360 psilocybin in treatment-resistant depression. The company said the application rests on two phase 3 trials and a phase 2b study that each met its primary end point, with more than 1,000 participants in all, and that COMP360 has been awarded a National Priority Voucher. Compass said it expects a launch in the first half of 2027, subject to FDA approval.Sources: Compass Pathways, Psychiatric Times
- Policy Nov 12, 2026The Food and Drug Administration (FDA) has shelved the Commissioner's National Priority Voucher program, according to a Nov. 12 Reuters report based on internal documents and sources, Psychiatric Times reported; FDA leadership told pharmaceutical companies the agency is not moving forward with the program but will keep applications open. The nine drugs still in the program include Compass Pathways' COMP360 psilocybin for treatment-resistant depression, Usona Institute's PSIL201 psilocybin and Transcend Therapeutics' TSND-201 methylone. A Department of Health and Human Services spokesperson said the pilot is ongoing and the FDA is reviewing feedback from a June public hearing.Source: Psychiatric Times
- Research Nov 10, 2026Johnson & Johnson said on Nov. 10 that in Study 452, the second pivotal phase 3 trial of Caplyta (lumateperone) for manic episodes, once-daily lumateperone 42 mg reduced Young Mania Rating Scale total score 3.7 points more than placebo at week 3 (effect size -0.43; P < .0001), in company-reported results. Clinical Global Impression-Severity scores also improved more than with placebo (P = .0003). The most common treatment-related adverse events were dizziness, dry mouth and somnolence or sedation. The company said two positive phase 3 studies will support a planned Food and Drug Administration submission for bipolar mania.Sources: Johnson & Johnson, Psychiatric Times
- Guidelines Nov 10, 2026The American Society of Addiction Medicine (ASAM) released clinical considerations on medetomidine intoxication and withdrawal on Nov. 10. Medetomidine, a veterinary sedative and alpha-2 adrenergic receptor agonist, has emerged as an adulterant associated with uniquely severe withdrawal, according to ASAM. According to Psychiatric Times, ASAM recommends alpha-2 agonist medications for withdrawal, with severe cases possibly requiring far higher doses than usual, and intravenous dexmedetomidine may be appropriate for severe tachycardia or hypertension. Naloxone remains essential in suspected overdose but does not reverse medetomidine, so patients may remain sedated, Psychiatric Times said.Sources: ASAM, Psychiatric Times
The weekly innovation roundup for psychiatry, published every Sunday for the week before; every item links to its sources. Latest psychiatry news · All specialties